SKU: 50182487551
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
glutathione cancer patient Tumor-targeted oxidation catalysis with ruthenium nanoreactors against hypoxic osteosarcoma Quantity:Single Vial Spot Reduction Frontiers | From laboratory
Frontiers | From laboratory to clinic: opportunities and challenges of functional food active ingredients in cancer therapy
As mentioned, CJC-1295 no DAC has not been researched in humans, so researchers may refer to the dosage of other GRF(1-29) analogs with similar modifications
Spot Reduction
Quantity:Single Vial
5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits
US$ 21.00
US$ 28.11
US$ 24.66
US$ 22.16
US$ 25.90
US$ 28.01
US$ 1417.31
Sold : Login>>
